Univariate and multivariate analysis of risk factors for OS and DFS (only with P ≤ .1) after ASCT in myelofibrosis
| Variable/category . | OS . | DFS . | ||||
|---|---|---|---|---|---|---|
| Kaplan-Meier 5-year OS (95% CI) . | Cox regression . | Kaplan-Meier 5-year DFS (95% CI) . | Cox regression . | |||
| HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Univariate | ||||||
| JAK2 type | ||||||
| JAK2V617F | 70% (62-78) | 1 | .007 | 50% (39-61) | 1 | .03 |
| JAK2-wt | 44% (30-58) | 2.23 (1.25-3.98) | 32% (19-45) | 1.71 (1.04-2.82) | ||
| Advanced age (continuous) | 1.07 (1.03-1.11) | .001 | 1.03 (1.00-1.06) | .05 | ||
| Lille score | .02 | |||||
| Low | 85% (75-95) | 1 | 70% (57-83) | 1 | .007 | |
| Intermediate + high | 55% (45-56) | 3.14 (1.25-7.92) | 36% (25-48) | 2.63 (1.30-5.31) | ||
| IPSS | ||||||
| Low + intermediate-1 | 86% (75-97) | 1 | .02 | 76% (61-91) | 1 | .01 |
| Intermediate-2 | 65% (54-76) | 1.64 (1.09-2.46) | 44% (28-60) | 2.96 (1.28-2.59 | ||
| High | 48% (34-62) | 33% (21-45) | ||||
| HLA match status | ||||||
| Matched | 67% (61-73) | 1 | .03 | 50% (41-59) | 1 | .05 |
| Mismatched | 36% (17-55) | 1.93 (1.05-3.53) | 26% (6-46) | 1.71 (1.00-2.92) | ||
| Multivariate, n = 135 | ||||||
| JAK2-wt | 2.14 (1.18-3.86) | .01 | ||||
| Advanced age (continuous) | 1.08 (1.04-1.13) | < .001 | ||||
| HLA mismatched | 1.95 (1.01-3.76) | .05 | 1.93 (1.08-3.49) | .03 | ||
| Lille intermediate + high score | 3.24 (1.57-6.70) | .002 | ||||
| Variable/category . | OS . | DFS . | ||||
|---|---|---|---|---|---|---|
| Kaplan-Meier 5-year OS (95% CI) . | Cox regression . | Kaplan-Meier 5-year DFS (95% CI) . | Cox regression . | |||
| HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Univariate | ||||||
| JAK2 type | ||||||
| JAK2V617F | 70% (62-78) | 1 | .007 | 50% (39-61) | 1 | .03 |
| JAK2-wt | 44% (30-58) | 2.23 (1.25-3.98) | 32% (19-45) | 1.71 (1.04-2.82) | ||
| Advanced age (continuous) | 1.07 (1.03-1.11) | .001 | 1.03 (1.00-1.06) | .05 | ||
| Lille score | .02 | |||||
| Low | 85% (75-95) | 1 | 70% (57-83) | 1 | .007 | |
| Intermediate + high | 55% (45-56) | 3.14 (1.25-7.92) | 36% (25-48) | 2.63 (1.30-5.31) | ||
| IPSS | ||||||
| Low + intermediate-1 | 86% (75-97) | 1 | .02 | 76% (61-91) | 1 | .01 |
| Intermediate-2 | 65% (54-76) | 1.64 (1.09-2.46) | 44% (28-60) | 2.96 (1.28-2.59 | ||
| High | 48% (34-62) | 33% (21-45) | ||||
| HLA match status | ||||||
| Matched | 67% (61-73) | 1 | .03 | 50% (41-59) | 1 | .05 |
| Mismatched | 36% (17-55) | 1.93 (1.05-3.53) | 26% (6-46) | 1.71 (1.00-2.92) | ||
| Multivariate, n = 135 | ||||||
| JAK2-wt | 2.14 (1.18-3.86) | .01 | ||||
| Advanced age (continuous) | 1.08 (1.04-1.13) | < .001 | ||||
| HLA mismatched | 1.95 (1.01-3.76) | .05 | 1.93 (1.08-3.49) | .03 | ||
| Lille intermediate + high score | 3.24 (1.57-6.70) | .002 | ||||
JAK2 status, age, Lille score, and match status were included in the multivariate analysis. IPSS scoring was excluded because of the transacting effect with Lille scoring.